Related references
Note: Only part of the references are listed.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Prudence A. Francis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Considerations for Digital PCR as an Accurate Molecular Diagnostic Tool
Jim F. Huggett et al.
CLINICAL CHEMISTRY (2015)
Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight
Suzanne A. W. Fuqua et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Bufalin Is a Potent Small-Molecule Inhibitor of the Steroid Receptor Coactivators SRC-3 and SRC-1
Ying Wang et al.
CANCER RESEARCH (2014)
Extending the Clinical Benefit of Endocrine Therapy for Women With Hormone Receptor-Positive Metastatic Breast Cancer: Differentiating Mechanisms of Action
Stefan Glueck
CLINICAL BREAST CANCER (2014)
Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2014)
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
Rinath Jeselsohn et al.
CLINICAL CANCER RESEARCH (2014)
The renaissance of endocrine therapy in breast cancer
Nicole Williams et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2014)
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Use of SERMs for treatment in postmenopausal women
Joann V. Pinkerton et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2014)
The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors
Osama E. Rahma et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Enhanced PI3K p110α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110α-Selective PI3K Inhibitor
Samuel W. Brady et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast
Salvatore Piscuoglio et al.
MOLECULAR ONCOLOGY (2014)
Clonal evolution in breast cancer revealed by single nucleus genome sequencing
Yong Wang et al.
NATURE (2014)
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Aaron M. Newman et al.
NATURE MEDICINE (2014)
Identification of Verrucarin A as a Potent and Selective Steroid Receptor Coactivator-3 Small Molecule Inhibitor
Fei Yan et al.
PLOS ONE (2014)
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
Min Yu et al.
SCIENCE (2014)
The Optimal Duration of Adjuvant Endocrine Therapy for Early Stage Breast Cancer-With What Drugs and for How Long?
Stephen R. D. Johnston et al.
CURRENT ONCOLOGY REPORTS (2014)
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers
Jamunarani Veeraraghavan et al.
NATURE COMMUNICATIONS (2014)
D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
Keren Merenbakh-Lamin et al.
CANCER RESEARCH (2013)
Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells
Albana Gattelli et al.
EMBO MOLECULAR MEDICINE (2013)
Improving T cell responses to modified peptides in tumor vaccines
Jonathan D. Buhrman et al.
IMMUNOLOGIC RESEARCH (2013)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study
Stephen X. Skapek et al.
PEDIATRIC BLOOD & CANCER (2013)
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
Shunqiang Li et al.
CELL REPORTS (2013)
Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer
L-Y Huw et al.
ONCOGENESIS (2013)
Sex Hormone Receptor Repertoire in Breast Cancer
Gerald M. Higa et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2013)
Estrogen receptors and human disease: an update
Katherine A. Burns et al.
ARCHIVES OF TOXICOLOGY (2012)
Acquired resistance to drugs targeting receptor tyrosine kinases
Steven A. Rosenzweig
BIOCHEMICAL PHARMACOLOGY (2012)
Prognostic Value of Estrogen Receptor α and Progesterone Receptor Conversion in Distant Breast Cancer Metastases
Laurien D. C. Hoefnagel et al.
CANCER (2012)
Elusive Extranuclear Estrogen Receptors in Breast Cancer
Ellis R. Levin
CLINICAL CANCER RESEARCH (2012)
Breast cancer intratumor genetic heterogeneity: causes and implications
Charlotte K. Y. Ng et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
ESR1 amplification in breast cancer: controversy resolved?
Donna G. Albertson
JOURNAL OF PATHOLOGY (2012)
Gene amplification of ESR1 in breast cancersufact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study
Akishi Ooi et al.
JOURNAL OF PATHOLOGY (2012)
Genetic heterogeneity and cancer drug resistance
Nicholas C. Turner et al.
LANCET ONCOLOGY (2012)
Direct mutation analysis by high-throughput sequencing: From germline to low-abundant, somatic variants
Michael Gundry et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Detection of ultra-rare mutations by next-generation sequencing
Michael W. Schmitt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
Ken Takezawa et al.
CANCER DISCOVERY (2012)
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment
S. C. Drury et al.
ENDOCRINE-RELATED CANCER (2011)
Progress in endocrine approaches to the treatment and prevention of breast cancer
Ifeyinwa Obiorah et al.
MATURITAS (2011)
Detection and quantification of rare mutations with massively parallel sequencing
Isaac Kinde et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305
Cinzia Giordano et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
WNT11 Expression Is Induced by Estrogen-Related Receptor α and β-Catenin and Acts in an Autocrine Manner to Increase Cancer Cell Migration
Mary A. Dwyer et al.
CANCER RESEARCH (2010)
New Strategies in Estrogen Receptor-Positive Breast Cancer
Stephen R. D. Johnston
CLINICAL CANCER RESEARCH (2010)
Growth factor stimulation induces a distinct ERα cistrome underlying breast cancer endocrine resistance
Mathieu Lupien et al.
GENES & DEVELOPMENT (2010)
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Advances in understanding cancer genomes through second-generation sequencing
Matthew Meyerson et al.
NATURE REVIEWS GENETICS (2010)
Phosphorylation of the mutant K303R estrogen receptor α at serine 305 affects aromatase inhibitor sensitivity
I. Barone et al.
ONCOGENE (2010)
ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: A multiplex ligation-dependent probe amplification study
Cathy B. Moelans et al.
ANALYTICAL CELLULAR PATHOLOGY (2010)
Potential of Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer
Jing Peng et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
Cancer research: from folate antagonism to molecular targets
Joseph R. Bertino
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients
Saori Tomita et al.
CANCER SCIENCE (2009)
The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer
Melanie Spears et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Absence of ESR1 amplification in a series of breast cancers
Jose Adelaide et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Next-generation DNA sequencing
Jay Shendure et al.
NATURE BIOTECHNOLOGY (2008)
NFκB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses
Kendall W. Nettles et al.
NATURE CHEMICAL BIOLOGY (2008)
ESR1 gene amplification in breast cancer:: a common phenomenon?
Anne Vincent-Salomon et al.
NATURE GENETICS (2008)
A role for glial cell-derived neurotrophic factor-induced expression by inflammatory cytokines and RET/GFRα1 receptor up-regulation in breast cancer
Selma Esseghir et al.
CANCER RESEARCH (2007)
Association between the estrogen receptor α A908G mutation and outcomes in invasive breast cancer
Matthew H. Herynk et al.
CLINICAL CANCER RESEARCH (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer
Frederik Holst et al.
NATURE GENETICS (2007)
Postmenopausal advanced breast cancer: Options for therapy after tamoxifen and aromatase inhibitors
D. Dodwell et al.
BREAST (2006)
Pure oestrogen antagonists for the treatment of advanced breast cancer
Anthony Howell
ENDOCRINE-RELATED CANCER (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators
R Schiff et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study
K Conway et al.
BREAST CANCER RESEARCH (2005)
Hypersensitive K303R oestrogen receptor-alpha variant not found in invasive carcinomas
MPA Davies et al.
BREAST CANCER RESEARCH (2005)
No hypersensitive estrogen receptor-α mutation (K303R) in Japanese breast carcinomas
E Tokunaga et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Increases in estrogen receptor-alpha concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen
AM Fowler et al.
FASEB JOURNAL (2004)
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - A prospective combined analysis of two multicenter trials
JFR Robertson et al.
CANCER (2003)
Nuclear receptor minireview series
JM Olefsky
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Estrogen receptor interaction with estrogen response elements
CM Klinge
NUCLEIC ACIDS RESEARCH (2001)
A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma
EF Mc Clay et al.
MELANOMA RESEARCH (2001)
Estrogen receptor pathways to AP-1
PJ Kushner et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2000)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
